* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Lee's Pharmaceutical Holdings's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lee's Pharmaceutical Holdings FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Lee's Pharmaceutical Holdings's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Lee's Pharmaceutical Holdings's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lee's Pharmaceutical Holdings (FRA:L1PA) has a FCF Margin % of 0.28% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Lee's Pharmaceutical Holdings and its competitors. This is 90% below median its historical median of 2.85. According to the industry distribution chart, Lee's Pharmaceutical Holdings ranks #356 out of 955 companies in the Drug Manufacturers industry, placing it in the top 37.3%.
Is Lee's Pharmaceutical Holdings' FCF Margin % too high?
Lee's Pharmaceutical Holdings' current FCF Margin % of 0.28% is 90% below median its 10-year median of 2.85. The Drug Manufacturers industry median FCF Margin % is 2.51. Lee's Pharmaceutical Holdings' value of 0.28% is 88.8% below this industry median. Based on the distribution chart, Lee's Pharmaceutical Holdings ranks #356 out of 955 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Lee's Pharmaceutical Holdings has a GF Score™ of 74/100, reflecting its overall financial health beyond just this single metric.
How does Lee's Pharmaceutical Holdings' FCF Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Lee's Pharmaceutical Holdings ranks #356 out of 955 companies for FCF Margin %. This puts Lee's Pharmaceutical Holdings in the upper half of its industry. The industry median FCF Margin % is 2.51. Lee's Pharmaceutical Holdings' value of 0.28% is 88.8% below this benchmark. While the company's 10-year median is 2.85 vs. the industry median of 2.51, Lee's Pharmaceutical Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.51, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lee's Pharmaceutical Holdings's current FCF Margin % of 0.28% is 88.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Lee's Pharmaceutical Holdings and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lee's Pharmaceutical Holdings's current FCF Margin % is 0.28%, which is 90% below median its own 10-year median of 2.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lee's Pharmaceutical Holdings stock overvalued right now?
Lee's Pharmaceutical Holdings (FRA:L1PA) has a current FCF Margin % of 0.28%. The stock's GF Value™ is €0.17, compared to a current price of €0.11 — trading 37.1% below its estimated fair value. The current FCF Margin % is 0.28%, which is 90% below median its 10-year median of 2.85 and 88.8% below the Drug Manufacturers industry median of 2.51. Lee's Pharmaceutical Holdings' overall GF Score™ is 74/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Lee's Pharmaceutical Holdings (FRA:L1PA), the current FCF Margin % is 0.28% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lee's Pharmaceutical Holdings (FRA:L1PA) Overvalued in 2026?
Based on GuruFocus' analysis, Lee's Pharmaceutical Holdings stock appears to be undervalued.
The current stock price of €0.11 is trading 37.1% below its estimated GF Value™ of €0.17.
Key valuation signals for FRA:L1PA:
FCF Margin %: 0.28% (90% below median its 10-year median of 2.85)
GF Value™: €0.17 vs. price of €0.11 (37.1% below fair value)
Industry Position: 88.8% below the Drug Manufacturers median (#356 of 955)
No single metric tells the full story. See the FRA:L1PA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lee's Pharmaceutical Holdings Business Description
Lee's Pharmaceutical Holdings Ltd is a research-driven and market-oriented biopharmaceutical company. Along with its subsidiaries, it develops, manufactures, sells, and markets pharmaceutical products. It focuses on cardiovascular, women's health, pediatrics, rare diseases, oncology, dermatology, and obstetrics. The company's reportable segments are; Proprietary and generic products which generates key revenue; and Licensed-in products. The Proprietary Products portfolio includes Livaracine, Yallaferon, Slounase, and Nadroparin Calcium Injection. Its Licensed-in Products include Centraxal Plus, Dicoflor, Ferplex, and Natulan among others. Geographically, the company generates a majority of its revenue from the People's Republic of China.
74GF Score
Get the complete analysis for FRA:L1PA
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:L1PA has been successfully added to your 
